Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Scientific Session

Immunobiology
General Topic: Basic Science

14T104: CARs as "Drivers" of Precision Cellular Immunotherapies for Autoimmune Diseases

Tuesday, November 14, 2023
7:30 AM - 8:30 AM PT
Location: Exhibit Hall A-B
CE: 1

On Demand In Person Livestreamed

    Speaker(s)

  • CH

    Chyi-Song Hsieh, MD, PhD

    Washington University
    St Louis, MO, United States

    Disclosure(s): No financial relationships with ineligible companies to disclose

  • MS

    Michel Sadelain, MD, PhD

    Memorial Sloan Kettering Cancer Center
    New York, NY, United States

    Disclosure(s): Atara Biotherapeutics, Inc.,: Grant/Research Support (Ongoing), Ownership Interest (Ongoing); Fate Therapeutics: Grant/Research Support (Ongoing), Ownership Interest (Ongoing); Juno Therapeutics: Ownership Interest (Ongoing); Mnemo Therapeutics: Grant/Research Support (Ongoing), Ownership Interest (Ongoing); Takeda Pharmaceutical Company, Ltd.,: Grant/Research Support (Ongoing), Ownership Interest (Ongoing)

  • Georg Schett, MD

    Friedrich-Alexander-Universität Erlangen-Nürnberg
    Erlangen, Germany

    Disclosure(s): No financial relationships with ineligible companies to disclose

Engineered T cell therapies targeting B cells, such as CD19-targeted chimeric antigen receptor (CAR)-T cells, have revolutionized the treatment of blood cancers and hold promise for treatment of patients with autoimmune diseases. Beyond conventional CARs, novel T cell engineering strategies provide unprecedented opportunities to develop antigen-specific precision cellular immunotherapies to selectively deplete autoreactive B cells or T cells in a given autoimmune or rheumatic disease, while preserving normal immune responses. This session will introduce learners to fundamentals in T cell engineering, juxtapose different engineering approaches that are being developed for antigen-specific targeting of autoreactive B cells or T cells, and highlight the extraordinary preliminary immune effects of immunotherapy for the treatment of autoimmunity

Learning Objectives:

  • Define the potential and risks of cellular immunotherapies for the treatment of organ-specific and systemic autoimmune diseases
  • Evaluate the immune system changes that result from CAR-T cell treatment in humans with lupus
  • Recognize approaches which may be employed to develop precision immunotherapies for the selective depletion of autoreactive T cells

Presentations:

  • 7:30 AM - 7:45 AM PT
    Methods for Cutting-Edge Engineering of the Immune System

    Speaker: Michel Sadelain, MD, PhD – Memorial Sloan Kettering Cancer Center

  • 7:45 AM - 8:00 AM PT
    Immunological Consequences of CAR T Cell Treatment of Refractory Systemic Lupus Erythematosus

    Speaker: Georg Schett, MD – Friedrich-Alexander-Universität Erlangen-Nürnberg

  • 8:00 AM - 8:15 AM PT
    Antigen-Specific Depletion of CD4+ T Cells in Experimental Autoimmune Encephalomyelitis

    Speaker: Chyi-Song Hsieh, MD, PhD – Washington University

  • 8:15 AM - 8:30 AM PT
    Q&A